Standard curve of SARS-CoV-2 Nucleocapsid Protein LFA Assay.
The LFA assay is developed by using SARS-CoV-2 Nucleocapsid Antibody (N338), mAb, mouse(GenScript, A02135) and MonoRab™ SARS-CoV-2 Nucleocapsid Antibody (N34), mAb, Rabbit(GenScript, A02136) as the capture and detection antibodies, respectively.
The combination shows good dose response of fluorescence intensity and concentrations of SARS-CoV-2 Nucleocapsid protein in LFA assay.
Nucleocapsid protein concentration was nicely correlated with fluorescence intensity.
Western Blot of wild-type and delta variant Nucleocapsid protein cell lysates with SARS-CoV-2 Nucleocapsid Antibody (N338), mAb, mouse (GenScript, A02135).
M: Protein Marker (GenScript, M00521)
Lane 1: 3 μg Wild-type N protein cell lysate
Lane 2: 3 μg Delta N protein cell lysate
Primary Antibody:
SARS-CoV-2 Nucleocapsid Antibody (N338), mAb, mouse (GenScript, A02135) 1 μg/ml
Secondary Antibody:
Anti-Mouse IgG (whole molecule)–Peroxidase antibody produced in rabbit (Sigma, A9044)
BLI (Biolayer interferometry) binding affinity measurements of SARS-CoV-2 Nucleocapsid Antibody (N338), mAb, mouse(GenScript, A02135) to SARS-CoV-2 Nucleocapsid protein of wild type and delta variant.
SARS-CoV-2 Nucleocapsid Antibody (N338) captured on Protein A sensors surface can bind wild-type or delta variant with dissociation constant (KD) of 3.62E-09M and 1.58E-09M.
![SARS-CoV-2 Nucleocapsid Antibody (N338), MAb, Mouse SARS-CoV-2 Nucleocapsid Antibody (N338), MAb, Mouse](/product/documents/down?doc_name=A02135_BLI-20211227.png&file=scm_files/productFile_notes/2021/12/28/62e2ba80-af4d-4f2d-94aa-d6d6162cb099.png)
BLI (Biolayer interferometry) binding affinity measurements of SARS-CoV-2 Nucleocapsid Antibody (N338), mAb, mouse (GenScript, A02135) to nucleocapsid protein of SARS-CoV-2 omicron variant.
SARS-CoV-2 Nucleocapsid Antibody (N338) captured on Protein A sensors surface can bind omicron variant with dissociation constant (KD) of 5.56E-09M.
SARS-CoV-2 Nucleocapsid Antibody (N338), mAb, mouse
A02135 | |
|
|
¥2500 | |
|
|
|
|
联系黄金城集团 |